CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
Pregabalin 50mg +2 moredrug
Likely dose
Pregabalin 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00706836
NCT00706836Phase 4Completed
CompareCT.gov

PharmacofMRI of Anxiolytic Medications (Pregabalin)

University of California, San Diego·interventional·Posted Jun 30, 2008·Updated Apr 9, 2019

In Brief

A Phase 4 clinical trial evaluating Pregabalin 50mg, Pregabalin 200 MG, and 1 other intervention for Anxiety Disorders. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy controls to examine the acute effects of certain anxiolytic medications on brain function. In this case, the medication pregabalin will be used. The investigators hypothesize that pregabalin (at doses of 50 mg and 200 mg, versus placebo) will yield a reduction in amygdala and insula activity (in a dose-dependent fashion) during emotion processing using fMRI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Disorders
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 30, 2008
Enrollment StartJun 1, 2008
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.0 years ago

Interventions

Pregabalin 50mgdrug

One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan

Pregabalin 200 MGdrug

One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan

placebodrug

One dose of matched oral placebo to be administered one hour prior to fMRI scan